vs
Orthofix Medical Inc.（OFIX）与医疗房产信托（SVC）财务数据对比。点击上方公司名可切换其他公司
医疗房产信托的季度营收约是Orthofix Medical Inc.的1.3倍（$296.5M vs $219.9M），医疗房产信托净利率更高（-0.3% vs -1.0%，领先0.7%），Orthofix Medical Inc.同比增速更快（2.0% vs -17.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-95.2M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -6.1%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
医疗房产信托（MPT）是总部位于阿拉巴马州伯明翰的国际房地产投资信托（REIT），主要在美国和欧洲地区收购投资医疗设施与营利性医疗控股公司。该公司的房产收购多采用售后回租模式，原产权方出售房产给MPT后成为承租租户，其租户普遍签订长期三净租约。
OFIX vs SVC — 直观对比
营收规模更大
SVC
是对方的1.3倍
$219.9M
营收增速更快
OFIX
高出18.9%
-17.0%
净利率更高
SVC
高出0.7%
-1.0%
自由现金流更多
OFIX
多$112.0M
$-95.2M
两年增速更快
OFIX
近两年复合增速
-6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $296.5M |
| 净利润 | $-2.2M | $-782.0K |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | -3.9% |
| 净利率 | -1.0% | -0.3% |
| 营收同比 | 2.0% | -17.0% |
| 净利润同比 | 92.4% | 99.0% |
| 每股收益（稀释后） | $-0.05 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXSVC
| Q4 25 | $219.9M | $296.5M | ||
| Q3 25 | $205.6M | $377.6M | ||
| Q2 25 | $203.1M | $404.4M | ||
| Q1 25 | $193.6M | $335.0M | ||
| Q4 24 | $215.7M | $357.0M | ||
| Q3 24 | $196.6M | $390.9M | ||
| Q2 24 | $198.6M | $412.5M | ||
| Q1 24 | $188.6M | $336.2M |
净利润OFIXSVC
| Q4 25 | $-2.2M | $-782.0K | ||
| Q3 25 | $-22.8M | $-46.9M | ||
| Q2 25 | $-14.1M | $-38.2M | ||
| Q1 25 | $-53.1M | $-116.4M | ||
| Q4 24 | $-29.1M | $-76.4M | ||
| Q3 24 | $-27.4M | $-46.9M | ||
| Q2 24 | $-33.4M | $-73.8M | ||
| Q1 24 | $-36.0M | $-78.4M |
毛利率OFIXSVC
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXSVC
| Q4 25 | 0.2% | -3.9% | ||
| Q3 25 | -8.3% | -12.8% | ||
| Q2 25 | -7.9% | -9.2% | ||
| Q1 25 | -25.2% | -33.3% | ||
| Q4 24 | -5.3% | -19.4% | ||
| Q3 24 | -9.6% | -12.8% | ||
| Q2 24 | -12.5% | -17.1% | ||
| Q1 24 | -15.6% | -21.4% |
净利率OFIXSVC
| Q4 25 | -1.0% | -0.3% | ||
| Q3 25 | -11.1% | -12.4% | ||
| Q2 25 | -6.9% | -9.4% | ||
| Q1 25 | -27.4% | -34.8% | ||
| Q4 24 | -13.5% | -21.4% | ||
| Q3 24 | -13.9% | -12.0% | ||
| Q2 24 | -16.8% | -17.9% | ||
| Q1 24 | -19.1% | -23.3% |
每股收益（稀释后）OFIXSVC
| Q4 25 | $-0.05 | $-0.01 | ||
| Q3 25 | $-0.57 | $-0.28 | ||
| Q2 25 | $-0.36 | $-0.23 | ||
| Q1 25 | $-1.35 | $-0.70 | ||
| Q4 24 | $-0.76 | $-0.46 | ||
| Q3 24 | $-0.71 | $-0.28 | ||
| Q2 24 | $-0.88 | $-0.45 | ||
| Q1 24 | $-0.95 | $-0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $346.8M |
| 总债务越低越好 | — | $5.5B |
| 股东权益账面价值 | $450.0M | $646.1M |
| 总资产 | $850.6M | $6.5B |
| 负债/权益比越低杠杆越低 | — | 8.52× |
8季度趋势，按日历期对齐
现金及短期投资OFIXSVC
| Q4 25 | $82.0M | $346.8M | ||
| Q3 25 | $62.9M | $417.4M | ||
| Q2 25 | $65.6M | $63.2M | ||
| Q1 25 | $58.0M | $80.1M | ||
| Q4 24 | $83.2M | $143.5M | ||
| Q3 24 | $30.1M | $48.6M | ||
| Q2 24 | $26.4M | $14.6M | ||
| Q1 24 | $27.0M | $71.3M |
总债务OFIXSVC
| Q4 25 | — | $5.5B | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | $5.8B | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXSVC
| Q4 25 | $450.0M | $646.1M | ||
| Q3 25 | $442.5M | $647.9M | ||
| Q2 25 | $458.3M | $695.9M | ||
| Q1 25 | $458.3M | $734.6M | ||
| Q4 24 | $503.1M | $851.9M | ||
| Q3 24 | $525.9M | $929.0M | ||
| Q2 24 | $546.0M | $1.0B | ||
| Q1 24 | $570.3M | $1.1B |
总资产OFIXSVC
| Q4 25 | $850.6M | $6.5B | ||
| Q3 25 | $832.6M | $7.0B | ||
| Q2 25 | $837.2M | $6.9B | ||
| Q1 25 | $823.1M | $7.0B | ||
| Q4 24 | $893.3M | $7.1B | ||
| Q3 24 | $867.9M | $7.1B | ||
| Q2 24 | $882.0M | $7.1B | ||
| Q1 24 | $906.0M | $7.2B |
负债/权益比OFIXSVC
| Q4 25 | — | 8.52× | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | 6.85× | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $-18.5M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $-95.2M |
| 自由现金流率自由现金流/营收 | 7.6% | -32.1% |
| 资本支出强度资本支出/营收 | 4.9% | 25.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $-107.0M |
8季度趋势，按日历期对齐
经营现金流OFIXSVC
| Q4 25 | $27.7M | $-18.5M | ||
| Q3 25 | $12.4M | $98.1M | ||
| Q2 25 | $11.6M | $-7.0K | ||
| Q1 25 | $-18.4M | $38.2M | ||
| Q4 24 | $23.7M | $-9.7M | ||
| Q3 24 | $11.7M | $106.2M | ||
| Q2 24 | $9.0M | $43.8M | ||
| Q1 24 | $-18.6M | $-926.0K |
自由现金流OFIXSVC
| Q4 25 | $16.8M | $-95.2M | ||
| Q3 25 | $2.5M | $57.9M | ||
| Q2 25 | $4.5M | $-46.6M | ||
| Q1 25 | $-25.1M | $-23.2M | ||
| Q4 24 | $15.2M | $-88.9M | ||
| Q3 24 | $6.3M | $24.1M | ||
| Q2 24 | $-360.0K | $-22.3M | ||
| Q1 24 | $-29.1M | $-77.2M |
自由现金流率OFIXSVC
| Q4 25 | 7.6% | -32.1% | ||
| Q3 25 | 1.2% | 15.3% | ||
| Q2 25 | 2.2% | -11.5% | ||
| Q1 25 | -13.0% | -6.9% | ||
| Q4 24 | 7.0% | -24.9% | ||
| Q3 24 | 3.2% | 6.2% | ||
| Q2 24 | -0.2% | -5.4% | ||
| Q1 24 | -15.4% | -23.0% |
资本支出强度OFIXSVC
| Q4 25 | 4.9% | 25.9% | ||
| Q3 25 | 4.8% | 10.6% | ||
| Q2 25 | 3.5% | 11.5% | ||
| Q1 25 | 3.5% | 18.3% | ||
| Q4 24 | 4.0% | 22.2% | ||
| Q3 24 | 2.7% | 21.0% | ||
| Q2 24 | 4.7% | 16.0% | ||
| Q1 24 | 5.6% | 22.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
SVC
暂无分部数据
